Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: The IMPROVE trial

Journal of Human Hypertension

Volumn 20, Issue 9, 2006, Pages 693-700

  Bakris, G L ^a   Ruilope, L ^b   Locatelli, F ^c   Ptaszynska, A ^d   Pieske, B ^e   Raz, I ^f   Voors, A A ^g   Dechamplain, J ^d   Weber, M A ^h  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c A MANZONI HOSPITAL   (Italy)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PLACEBO; RAMIPRIL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MICROALBUMINURIA; MONOTHERAPY; MULTICENTER STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 33747792696     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002050     Document Type: Article

References (38)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2004; 41: 47-55.
3. Anakevar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295.
4. Hall WD. Abnormalities in kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317: 176-182.
5. Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22: 1635-1639.
6. Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13(suppl 3): S165-S168.
7. Guidelines Committee. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
8. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
9. Segura J, Campo C, Gil P, Roldan C, Vigil L, Ridicio JL et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616-1622.
10. Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; 66: S45-S49.
11. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14: 881-887.
12. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf F. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
13. Ibsen H, Olsen MH, Wachtell K, Bosch-Johnsen K, Lindholm LH, Mogensen CE et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
14. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
15. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.
16. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
17. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigay PJ et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
18. Kistorp C, Raymond I, Pederson F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
19. Garg JP, Bakris GL. Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002; 7: 35-43.
20. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. Albuminuria and risk-of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
21. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21: 1213-1220.
22. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
23. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-647.
24. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886.
25. Nakao N, Yoshimura A, Morita H, Takada M, Kawahara H, Fukagawa M. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 2003: 3361: 117-124.
26. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy. Am J Nephrol 2004; 24: 543-548.
27. Segura J, Garcia Donaire JA, Ruilope LM. Calcium channel blockers and renal protection, insights from the latest clinical trials. J Am Soc Nephrol 2005; 16: S64-S66.
28. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17: 590-596.
29. Ruggenenti. P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
30. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003; 139: 901-906.
31. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B et al., the ONTARGET/TRANSCEND investigators. Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
33. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001: 345: 851-860.
34. Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrani G. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004; 92: S99-S101.
35. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001; 285: 2719-2728.
36. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421-2431.
37. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595-600.
38. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153